[单项选择] Under existing law, a new drug may be labeled, promoted, and advertised only for those conditions in which safety and effectiveness have been demonstrated and which the Food and Drug Administration (FDA) has approved, or so-called approved uses. Other uses have come to be called "unapproved uses", and cannot be legally promoted. In a real sense, the term "unapproved" is a misnomer because it includes one phrase two categories of marketed drugs that are very different. It is common for new research and new insights to identify valid new uses for drugs already on the market. Before such advances can result in new indications for inclusion in drug labeling, however, the available data must meet the legal standard of substantial evidence derived from adequate and well-controlled clinical trials. Such evidence may require time to develop, and, without initiative on the part of the drug firm, it may not occur at all for certain uses. However, because medical literature on new uses exi
A. prohibiting the unlabeled use
B. permitting the disapproved use
C. allowing the practice of the unlabeled use
D. hastening their approval of the disapproved use

[单项选择]

Under existing law, a new drug may be labeled, promoted, and advertised only for those conditions in which safety and effectiveness have been demonstrated and of which the Food and Drug Administration (FDA) has approved, or so-called "approved uses." Other uses have come to be called "unapproved uses" and cannot be legally promoted. In a real sense, the term "unapproved’ is a misnomer because it includes in one phrase two categories of marketed drugs that are very different; drugs which are potentially harmful and will never be approved, and already approved drugs that have "unapproved" uses. It is common for new research and new insights to demonstrate valid new uses for drugs already on the market. Also, there are numerous examples of medical progress resulting from the serendipitous observations and therapeutic innovations of physicians, both important methods of discovery in the field of therapeutics. Bef
A. the increased cost to the patient of buying an FDA-approved drug
B. the medical benefits which can accrue to the patient through unlabeled use
C. the time lag between initial discovery of a medical use and FDA approval of that use .
D. the possibility that a medically beneficial use may never be clinically documented